HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Alexander Kaminski Can Yerebakan Andreas Liebold Gustav Steinhoff Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donndorf, P. Articles by Glass, A. Search for Related Content PubMed PubMed Citation Articles by Donndorf, P. Articles by Glass, A. Related Collections Congestive Heart Failure Coronary disease

J Thorac Cardiovasc Surg 2011;142:911-920
© 2011 The American Association for Thoracic Surgery

Evolving Technology/Basic Science

Intramyocardial bone marrow stem cell transplantation during coronary artery bypass surgery: A meta-analysis

^a Department of Cardiac Surgery, University of Rostock, Rostock, Germany
^b Institute for Biostatistics and Informatics in Medicine and Ageing, Research, University of Rostock, Rostock, Germany

Received for publication July 13, 2010; revisions received October 18, 2010; accepted for publication December 9, 2010.

^_* Address for reprints: Peter Donndorf, MD, Department of Cardiac Surgery, University of Rostock, Schillingallee 35, 18057 Rostock, Germany. (Email: peter.donndorf{at}med.uni-rostock.de).

Objective: Experimental and clinical studies have suggested that intramyocardial bone marrow stem cell transplantation combined with coronary artery bypass grafting might improve left ventricular function in the setting of chronic ischemic heart disease. We therefore conducted a systematic review and meta-analysis of available publications regarding the efficacy and safety of intramyocardial bone marrow stem cell transplantation during coronary artery bypass grafting.

Methods: The databases PUBMED, MEDLINE, Cochrane Controlled Trials Register, and ClinicalTrials.gov (all from their inception to May 2009) were searched for randomized controlled trials and cohort studies of intramyocardial bone marrow stem cell transplantation during coronary artery bypass grafting to treat ischemic heart disease. Six studies were included.

Results: Compared with control groups, the bone marrow stem cell transplantation group showed a significant improvement of left ventricular ejection fraction from baseline to follow-up (5.40%; 95% confidence interval, 1.36–9.44; P = .009). Moreover, the overall change of left ventricular end-diastolic volume from baseline to follow-up favored the bone marrow stem cell therapy group (9.55 mL; 95% confidence interval, –2.82 to 21.92; P = .13). Major adverse cardiovascular events, including ventricular arrhythmia and the composite of other cardiovascular events, were not significantly different between the bone marrow stem cell therapy group and controls (relative risk for ventricular arrhythmia = 0.951; 95% confidence interval, 0.389–2.325; P = .913; relative risk for cardiovascular event = 1.134; 95% confidence interval, 0.28–4.6; P = .86).

Conclusions: Clinical evidence suggests that intramyocardial bone marrow stem cell transplantation in combination with coronary artery bypass grafting is associated with improvements of functional parameters in patients with chronic ischemic heart disease. Furthermore, surgical intramyocardial bone marrow stem cell transplantation seems to be safe.

This article has been cited by other articles:

				A. Shafy, T. Fink, V. Zachar, N. Lila, A. Carpentier, and J. C. Chachques Development of cardiac support bioprostheses for ventricular restoration and myocardial regeneration Eur J Cardiothorac Surg, June 1, 2013; 43(6): 1211 - 1219. [Abstract] [Full Text] [PDF]